RANI (Rani Therapeutics Holdings, Inc.) Utang jangka cendhak marang modal

Rani Therapeutics (RANI) creates innovative RaniPill capsules to replace injections, raising funds through licenses with market leaders. A team of engineers and biologists is developing "smart pills," receiving options for breakthroughs. This chart on GURU.Markets for the separate_debt_short_eq metric shows 0.03. Future growth relies on the success of clinical trials and the management of R&D expenses.

For Rani Therapeutics (RANI), which monetizes its innovative "robo-pill" through licensing agreements, the ratio of short-term liabilities to equity reflects the balance between operational development and debt load. This coefficient measures the proportion of liabilities with a maturity exceeding one year within the capital structure, where increasing values indicate heightened financial risks, while a decrease confirms the issuer's solvency stability.